On 9/17/25, Cara Therapeutics Inc (NASDAQ: CARA) stock enjoyed a major increase of 15.4%, closing at $39.04. Moreover, trading volume in this advance was exceptionally high at 434% of normal. The stock has risen 22.7% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Cara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment